Skip to main content

Anti-obesity drugs


05-10-2017 | Liraglutide (T2DM) | News

Liraglutide link with pancreatitis unlikely

Taking the glucagon-like peptide-1 receptor agonist liraglutide does not increase patients’ risk for acute pancreatitis during more than 3 years of treatment, show two reports analyzing the LEADER and SCALE trials.

05-04-2017 | Obesity | News

Assessing diabetes risk could optimize effectiveness of weight loss therapy

Targeting obese patients for weight-loss therapy according to their cardiometabolic status could much improve its effectiveness for diabetes prevention, say researchers.

02-23-2017 | Liraglutide (Obesity) | News

Liraglutide boosts preventive power of lifestyle intervention in prediabetes

Liraglutide enhances the positive effects of lifestyle intervention on weight loss and glycemic control in patients with prediabetes, show the 3-year outcomes of the SCALE Obesity and Prediabetes trial.

Read more

Related topics




Journal articles and book chapters

05-14-2017 | Obesity | Review | Article

Medication use for the treatment of diabetes in obese individuals

In this review, Wilding discusses the main pharmacological approaches that can be used to support weight loss in individuals with diabetes.

Wilding JPH. Diabetologia 2017. doi:10.1007/s00125-017-4288-1

04-19-2017 | Obesity | Review | Article

Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?

In personalizing pharmacotherapy for obesity in adults, it is critical that the behavioral issues associated with obesity are targeted. This review summarizes the multitude of considerations that must be made.

Roberts CA et al. Acta Diabetol 2017. doi:10.1007/s00592-017-0994-x

01-18-2017 | Obesity | Review | Article

Medical management of diabesity: Do we have realistic targets?

“Diabesity”—diabetes related to obesity—has become increasingly prevalent over the past few decades because of the obesity epidemic. This review discusses the key issues and realistic targets for diabesity management.

Pappachan JM & Viswanath AK. Curr Diab Rep 2017; 17: 4. doi:10.1007/s11892-017-0828-9